Status:
COMPLETED
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
Lead Sponsor:
Medivation, Inc.
Collaborating Sponsors:
Huntington Study Group
Conditions:
Huntington's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Als...
Eligibility Criteria
Inclusion
- Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
- Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale
Exclusion
- Clinical evidence of unstable medical illness
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00387270
Start Date
October 1 2006
End Date
March 1 2007
Last Update
January 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntington Study Group
Rochester, New York, United States, 14620